Collaborate
with Us

We believe that collaboration plays a critical role in helping us meet our goal of discovering, developing, and commercializing transformative medicines.

We have multiple active collaborations that are advancing research and development of novel therapeutic programs. Additionally, our collaborations are extending the reach of our PRISMTM discovery and drug development platform into therapeutic areas where we may offer a competitive advantage in R&D for oligonucleotide compounds. If you share our vision for unlocking the full potential of RNA medicines and are interested in leveraging our PRISM discovery and drug development platform, contact our Business Development team at [email protected].

  • GSK

    Our collaboration with GSK aims to advance transformative oligonucleotide therapeutics, including WVE-006 for alpha-1 antitrypsin deficiency (AATD). The collaboration combines GSK’s unique insights from human genetics, as well as its global development and commercial capabilities, with Wave’s PRISMTM platform and oligonucleotide expertise. It has three components:

    • A discovery collaboration which enables Wave to advance up to three programs leveraging targets informed by GSK’s novel insights;
    • A discovery collaboration which enables GSK to advance up to eight programs leveraging Wave’s discovery capabilities and PRISM, including Wave’s three RNA-targeting modalities (editing, splicing, and silencing);
    • An exclusive global license for GSK to WVE-006, Wave’s program for AATD that uses proprietary “AIMer” technology (A-to-I(G) RNA base editing). WVE-006 is a first-in-class RNA editing therapeutic that is designed to address both liver and lung manifestations of the disease. Wave will maintain development responsibilities for WVE-006 through completion of the first clinical study, at which point development and commercial responsibilities will transition to GSK.

    Read the collaboration press release

  • Takeda
    Our collaboration with Takeda Pharmaceuticals aims to accelerate the development of innovative, first-in-class therapies that address central nervous system (CNS) disorders. As part of this strategic partnership, Takeda has an option to a global 50:50 co-development and co-commercialization profit share for select CNS targets, including huntingtin (WVE-003 for Huntington’s disease).